 Connection
Brian Day to Administration, Oral
This is a "connection" page, showing publications Brian Day has written about Administration, Oral.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.253 |
|
|
|
-
Hamzeh N, Li L, Barkes B, Huang J, Canono B, Gillespie M, Maier L, Day B. The effect of an oral anti-oxidant, N-Acetyl-cysteine, on inflammatory and oxidative markers in pulmonary sarcoidosis. Respir Med. 2016 Mar; 112:106-11.
Score: 0.110
-
Kariya C, Leitner H, Min E, van Heeckeren C, van Heeckeren A, Day BJ. A role for CFTR in the elevation of glutathione levels in the lung by oral glutathione administration. Am J Physiol Lung Cell Mol Physiol. 2007 Jun; 292(6):L1590-7.
Score: 0.060
-
Liang LP, Fulton R, Bradshaw-Pierce EL, Pearson-Smith J, Day BJ, Patel M. Optimization of Lipophilic Metalloporphyrins Modifies Disease Outcomes in a Rat Model of Parkinsonism. J Pharmacol Exp Ther. 2021 04; 377(1):1-10.
Score: 0.039
-
Liang LP, Huang J, Fulton R, Pearson-Smith JN, Day BJ, Patel M. Pre-clinical therapeutic development of a series of metalloporphyrins for Parkinson's disease. Toxicol Appl Pharmacol. 2017 07 01; 326:34-42.
Score: 0.030
-
Liang LP, Huang J, Fulton R, Day BJ, Patel M. An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo. J Neurosci. 2007 Apr 18; 27(16):4326-33.
Score: 0.015
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|